Reported 4 months ago
The US Food and Drug Administration (FDA) is set to vote on recommendations for updated COVID-19 booster shots due to the spread of the KP.2 variant strain. Yahoo Finance Health Reporter Anjalee Khemlani discusses the impact on vaccine makers like Novavax (NVAX), whose stock has surged. Novavax stands to benefit the most if the FDA recommends focusing on the J and one variant strain. The potential fall booster campaign is seen as important for those who are immune deficient, while the overall American population is considered adequately protected against known variants.
Source: YAHOO